Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
Recruiting
This is an open label, two to three center study to evaluate the clinical efficacy and safety of 1 dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes with diabetic kidney disease (DKD) and proteinuria.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2025
Locations: Clinical Advancement Center, PLLC, San Antonio, Texas
Conditions: Diabetic Kidney Disease
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
Recruiting
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Retina Consultants of Texas Research Centers, Bellaire, Texas
Conditions: Retinitis Pigmentosa, Choroideremia
Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia
Recruiting
The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related measures and symptoms of schizophrenia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: The University of Texas health Science Center at Houston, Houston, Texas
Conditions: Smoking Cessation
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Recruiting
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes.... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/10/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study,... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2025
Locations: Novel Research, LLC, Bellaire, Texas
Conditions: Ulcerative Colitis
A Prospective Study of a Modified Lumbar Puncture (LP) Procedure That Reduces Post-Lumbar Puncture Headaches (PLPH) in Patients
Recruiting
The purpose of this study is to o determine whether the modified LP procedure reduces the incidence of PLPH to 5% or lower, to determine whether the modified LP procedure reduces the frequency of epidural blood patch (EBP) usage to 10% or lower of the PLPH population and to identify factors that may contribute to or reduce incidence of PLPH
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Post-Lumbar Puncture Headache
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Recruiting
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.
Gender:
ALL
Ages:
1 year and below
Trial Updated:
06/10/2025
Locations: MD Anderson, Houston, Texas
Conditions: Lymphoblastic Leukemia
Lexion AP 50/30 Warmed Humidified Real Time CO2 Insufflation vs Airseal Recirculated CO2/Air Insufflation in Minimally Invasive Bariatric (Gastric Bypass) Surgery
Recruiting
The purpose of this study is to To determine the effect of warm and humidified (WH) carbon dioxide (CO2) on post-operative pain/analgesia requirement in patients undergoing laparoscopic bariatric surgery.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/10/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Bariatric Surgery
Thoraflex Hybrid and Relay Extension Post-Approval Study
Recruiting
The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting the aortic arch and descending aorta with or without involvement of the ascending aorta. Patients who undergo treatment with the Thoraflex Hybrid device with or without extension with a RelayPro NBS stent-graft will be eligible for enrolment and study activities and follow-up regime will follow standard care at ea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: UT Dell Medical / Ascension Texas Cardiovascular, Austin, Texas
Conditions: Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm, Thoracic Aortic Dissection
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Recruiting
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects wit... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/10/2025
Locations: North Pointe Psychiatry - Flower Mound, Flower Mound, Texas
Conditions: Psychosis Associated With Alzheimer's Disease
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
Recruiting
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/10/2025
Locations: Texas Liver Institute, San Antonio, Texas
Conditions: Hepatic Impairment, Cirrhosis
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Recruiting
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1) and aged ≥6 to \<48 months (Part 2). Part 1 follows an open-label, dose-escalation design, and Part 2 is a randomized, double-blind, sham delayed-treatment control, dose-selection study.
Gender:
ALL
Ages:
Between 6 months and 47 months
Trial Updated:
06/10/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Dravet Syndrome